Yahoo Web Search

Search results

1. ascopost.com › news › june-2024Osimertinib for Patients With Locally Advanced EGFR-Mutated ...

   ascopost.com › news › june-2024

   • Cached

   2 days ago · “The LAURA trial is the first to define the role of EGFR-directed therapy in unresectable stage III [NSCLC].While the study did not compare osimertinib to the current standard-of-care immunotherapy, these data have major implications for both patients and oncologists and will change the standard of care for patients with [lung cancer and] EGFR mutations,” said David R. Spigel, MD, Chief ...

2. Images

   • 
   • 
   • 
   • 
   • 

   View all

3. dailynews.ascopubs.org › do › laura-osimertinibLAURA: Osimertinib Significantly Improves PFS in Unresectable ...

   dailynews.ascopubs.org › do › laura-osimertinib

   2 days ago · The LAURA trial is the first phase 3 study to assess a targeted agent in patients with unresectable stage III NSCLC. It included a total of 216 patients from 17 countries randomly assigned 2:1 to receive either osimertinib (143 patients) or placebo (73) patients. The majority of patients in the study were female (63% in the osimertinib group ...

4. www.cancertherapyadvisor.com › features › asco-2024ASCO 2024: Research Roundup - Cancer Therapy Advisor

   www.cancertherapyadvisor.com › features › asco-2024

   • Cached

   3 days ago · Breast Cancer. Results from the ... III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. ASCO 2024. May 31 – June 4, 2024. Abstract LBA4. ...

5. www.prnewswire.com › news-releases › sarcomaSARCOMA CLINICAL TRIAL FUNDED BY STAND UP TO CANCER REDUCES ...

   www.prnewswire.com › news-releases › sarcoma

   • Cached

   6 hours ago · The late Laura Ziskin and the late Noreen Fraser are also co-founders. Julian Adams , Ph.D., serves as SU2C's president and CEO. For more information, visit StandUpToCancer.org , Instagram ...

6. pharmaphorum.com › news › asco-astrazenecas-tripleASCO: AstraZeneca’s triple whammy in lung and breast cancer

   pharmaphorum.com › news › asco-astrazenecas-triple

   • Cached

   1 day ago · Jonah Comstock. Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress. Three of the group’s top cancer drugs were on ...

7. translational-medicine.biomedcentral.comThe transcriptional landscape of cancer stem-like cell ...

   translational-medicine.biomedcentral.com

   • Cached

   1 day ago · Background Cancer stem-like cells (CSCs) have been extensively researched as the primary drivers of therapy resistance and tumor relapse in patients with breast cancer. However, due to lack of specific molecular markers, increased phenotypic plasticity and no clear clinicopathological features, the assessment of CSCs presence and functionality in solid tumors is challenging. While several ...

8. my.clevelandclinic.org › podcasts › cancer-advancesPeptide Therapy Innovations for Triple Negative Breast Cancer

   my.clevelandclinic.org › podcasts › cancer-advances

   • Cached

   5 days ago · The Cancer Advances podcast is joined by Ofer Reizes, PhD, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research, and Justin Lathia, PhD, Melvin H. Burkhardt Endowed Chair for Neuro-Oncology Research, Scientific Director of the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, and the Vice Chair of the Department of Cardiovascular and Metabolic Sciences at Cleveland Clinic's ...